// App-Quantinova.ai

4194 : Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but Persistence of Late Acute Gvhd

Researchers

Presenter

  • Sean Devlin

Principal Investigators

  • Craig S. Sauter

  • Juliet N Barker

  • Hugo Castro-Malaspina

  • Sergio A Giralt

  • Doris M Ponce

  • Lauren Lechner

  • Anne Marie R Gonzales

  • Jenna D Goldberg

  • Miguel-Angel Perales

Medical Centers

  • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Complejo Hospitalario de Navarra, Pamplona, Spain

Locations

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Thrombotic microangiopathy

  • Graft-versus-host disease

  • Hematological malignancies

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • Myelodysplastic Syndrome

  • Nephrotoxicity

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Methotrexate

  • Tacrolimus

  • Rapacan

  • Rituximab

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved